Physician profile
Jeffrey E Fegan
NPI 1982674594
$374.01
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $63.74 · 2021: $79.14.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $170.51 | 2019-2020 | |
| Astellas Pharma US INC | $107.38 | 2019-2020 | |
| Laborie Medical Technologies Corp. | $33.10 | 2021 | |
| Axonics, INC. | $31.95 | 2021 | |
| Ambu INC. | $16.98 | 2020 | |
| Urogen Pharma, INC. | $14.09 | 2021 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$0.05 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Fegan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.